To the Editor,
In the Continuing Professional Development article, Assessment and treatment of preoperative anemia, Hare et al.
1 present very interesting concepts and hypotheses. Despite the important concepts, implementation of the proposed protocol would inevitably result in delays as well as logistical and financial implications related to the supervised administration of intravenous iron and erythropoietic stimulating agents (ESAs). Also, it is questionable whether the evidence is sufficiently strong to incorporate the proposed protocol into routine clinical practice.
The protocol in the article appears to be based on the Network for Advancement of Transfusion Alternatives (NATA) guidelines, 2 which were directed specifically toward elective orthopedic surgical patients. The authors of the NATA guidelines made five recommendations graded as strong or weak according to the risk/benefit ratio, and they classified the respective quality of evidence as high, moderate, or low/very low. There are three strong recommendations regarding the timing of testing, laboratory tests, and the treatment of nutritional deficiency anemia, yet the recommendations are based on low/very low-quality evidence. Also, a weak recommendation regarding the target hemoglobin level is based on low/very low-quality evidence. The only recommendation based on high-quality evidence is the final weak recommendation regarding the use of ESAs in anemia where nutritional deficiency has been ruled out.
The same group also produced a consensus statement 3 regarding the use of intravenous iron wherein they concluded that intravenous iron may be indicated in the perioperative period in orthopedic patients who are expected to develop severe postoperative anemia. Again, this is a weak recommendation based on moderate/ lowquality evidence, and no evidence-based recommendations could be made for other types of surgery. With regard to the use of ESAs in cancer patients, the European Medicines Agency recommends that transfusion be the preferred method for correcting anemia in cancer patients, especially those with a long life expectancy. 4 The Food and Drug Administration changed the product label for ESAs by adding a black box warning which specifies that ESAs are not indicated to treat cancer-induced anemia in patients not on chemotherapy or in patients with potentially curable cancer. These recommendations were echoed by the American Society of Clinical Oncology clinical practice guidelines. 5 
Reply
The authors appreciate the comments of Dr. Verniquet with respect to concerns about important practical aspects of anemia treatment in perioperative patients. The proposed treatment protocol is based on standard clinical approaches to the treatment of anemia associated with iron deficiency and inflammatory conditions, the most common forms of anemia in perioperative patients. These recommendations are consistent with the Network for Advancement of Transfusion Alternatives guidelines. In addition, the concerns raised about potential toxicity of therapies, including intravenous iron and erythrocyte stimulating agents, must be considered. The authors agree that care must be taken when utilizing erythropoietic stimulating agent therapy, and practitioners must be aware of the relative and absolute contraindications for its use-as addressed in our Continuing Professional Development module. When utilizing any therapy, the treatment must be individualized to the specific patient circumstances, and the potential for therapeutic benefit must always be balanced by consideration for the risk of adverse effects. Unfortunately, there is limited prospective randomized outcome data to support the benefit of anemia treatment in cardiac and non-cardiac surgery. This may be a result of previously published reports which supported a different perspective, namely, that anemia is safe, 1 adaptive, 2 and therapeutic. 3 However, these studies were not undertaken in patients undergoing surgery who experience hemodynamic stress associated with acute blood loss, surgical trauma, and inflammation. An increasing number of clinical studies have shown that acute anemia is an independent predictor for increased mortality in this patient population. The magnitude of this problem is emphasized by two recently published retrospective studies which demonstrate that up to 30-50% of our patients suffer from preoperative anemia and that even mild to moderate anemia is associated with significant increases in perioperative mortality. 4, 5 In addition, a newly published experimental study emphasizes that these adverse clinical outcomes likely occur through complex mechanisms that include both hypoxic and nonhypoxic cellular responses. 6 These data strongly support the need for appropriately powered randomized trials to determine if treatment of anemia can improve outcome and reduce mortality in our patients. In addition, in order to develop other novel and effective treatment strategies, studies are also required that define the adaptive mechanism(s) that protect against anemia-induced mortality.
